Stockreport

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease [Yahoo! Finance]

Longeveron Inc. - common stock  (LGVN) 
PDF Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive fu [Read more]